Judith Dunn - 19 Jan 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Reporting relationship: President, Research & Development
Issuer ticker: FULC
Reported as of: 19 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2022, 15:15:31 UTC
Prior SEC filing: 09 Aug 2021
Next SEC filing: 01 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Peter Thomson, as attorney-in-fact for Judith A. Dunn

Key filing fact

Judith Dunn filed Form 4 for Fulcrum Therapeutics, Inc. (FULC) on 21 Jan 2022.

Key facts

This page summarizes Judith Dunn's Form 4 filing for Fulcrum Therapeutics, Inc. (FULC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2022, 15:15.

Change

Previous filing in this sequence was filed on 09 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FULC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +140,890
Change %
Price: $0.000000
Shares after: 140,890
Date: 19 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 140,890
Exercise price: $12.69
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

SEC remarks

President, Research & Development